Sugi Predict

Sugi Predict / Compounds / SCHEMBL553315

SCHEMBL553315

SCHEMBL553315

COC(=O)c1ccc(Cn2cccn2)c(OC)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KLKB1 P03952 1/20 0.47
▸ TLR7 Q9NYK1 1/20 0.47
▸ HDAC6 Q9UBN7 2/20 0.46
▸ HDAC1 Q13547 1/20 0.46
▸ LMNA P02545 1/20 0.45
▸ MAPT P10636 2/20 0.45
▸ KAT7 O95251 1/20 0.45
▸ KAT6B Q8WYB5 1/20 0.45
▸ KAT6A Q92794 1/20 0.45
▸ HTT P42858 3/20 0.44
▸ GAA P10253 2/20 0.44
▸ USP2 O75604 1/20 0.44
▸ MEN1 O00255 3/20 0.44
▸ KMT2A Q03164 3/20 0.44
▸ NPSR1 Q6W5P4 2/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ TSHR P16473 1/20 0.43
▸ ADRB2 P07550 1/20 0.42
▸ ADRB1 P08588 1/20 0.42
▸ ADRB3 P13945 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31172671 0.89 HTT (0.56) KLKB1HDAC6HDAC1LMNAMAPT
SCHEMBL31172762 0.89 HTT (0.56) KLKB1HDAC6HDAC1LMNAMAPT
SCHEMBL31172710 0.88 MAPK1 (0.49) KLKB1HDAC6HDAC1LMNAMAPT
SCHEMBL31172603 0.88 MAPK1 (0.49) KLKB1HDAC6HDAC1LMNAMAPT
SCHEMBL31172672 0.87 KAT7 (0.42) KLKB1HDAC6HDAC1LMNAMAPT
SCHEMBL31172674 0.87 KAT7 (0.48) KLKB1TLR7HDAC6HDAC1KAT7
SCHEMBL31172618 0.87 HDAC1 (0.42) KLKB1TLR7HDAC6HDAC1LMNA
SCHEMBL17221669 0.85 KLKB1 (0.50) KLKB1HDAC6HDAC1LMNAKAT7
SCHEMBL31691302 0.85 HDAC1 (0.46) KLKB1HDAC6HDAC1LMNAMAPT
SCHEMBL31172517 0.85 HDAC1 (0.49) KLKB1HDAC6HDAC1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680226-A2 ACYLSULFONAMIDE KAT6A INHIBITORS Olema Pharmaceuticals, Inc. (US) 2026-01-21 — — EP disclosed
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS INC (US) 2026-01-15 — — US disclosed
US-20250304535-A1 KAT6 Inhibitors BEIGENE SWITZERLAND GMBH (CH) 2025-10-02 — — US disclosed
WO-2025201504-A1 KAT6 INHIBITORS BEIGENE (SUZHOU) CO., LTD. (CN) 2025-10-02 — — WO disclosed
US-12428379-B2 Acylsulfonamide KAT6A inhibitors OLEMA PHARMACEUTICALS, INC. (US) 2025-09-30 — — US disclosed
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. 2025-05-01 — — US disclosed
WO-2024189598-A2 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. (US) 2024-09-19 — — WO disclosed
US-9290485-B2 N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides NOVARTIS AG (CH) 2016-03-22 — — US disclosed
US-9290485-B2 N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides NOVARTIS AG (CH) 2016-03-22 — — US disclosed
US-9290485-B2 N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides NOVARTIS AG (CH) 2016-03-22 — — US disclosed
EP-2601189-B1 N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES AS INHIBITORS OF PLASMA KALLIKREIN NOVARTIS AG (CH) 2015-04-15 — — EP disclosed
EP-2601189-B1 N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES AS INHIBITORS OF PLASMA KALLIKREIN NOVARTIS AG (CH) 2015-04-15 — — EP disclosed
CN-103080104-B N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides as inhibitors of plasma kallikrein NOVARTIS AG 2015-04-08 — — CN disclosed
EP-2601189-A1 N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES AS INHIBITORS OF PLASMA KALLIKREIN Novartis AG (CH) 2013-06-12 — — EP disclosed
CN-103080104-A N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides as inhibitors of plasma kallikrein NOVARTIS AG 2013-05-01 — — CN disclosed
US-20120035168-A1 N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES NOVARTIS AG (CH) 2012-02-09 — — US disclosed
US-20120035168-A1 N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES NOVARTIS AG (CH) 2012-02-09 — — US disclosed
US-20120035168-A1 N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES NOVARTIS AG (CH) 2012-02-09 — — US disclosed
WO-2012017020-A1 N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES AS INHIBITORS OF PLASMA KALLIKREIN NOVARTIS AG (CH) 2012-02-09 — — WO disclosed
WO-2012017020-A1 N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES AS INHIBITORS OF PLASMA KALLIKREIN NOVARTIS AG (CH) 2012-02-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B KLKB1 1815/4885TLR7 4578/4885HDAC6 8/4885
US-20250304535-A1 KAT6 Inhibitors KAT6A, KAT6B, KAT2A KLKB1 2673/4885TLR7 3808/4885HDAC6 11/4885
US-12428379-B2 Acylsulfonamide KAT6A inhibitors KAT6A, KAT2A, KAT6B KLKB1 1815/4885TLR7 4578/4885HDAC6 8/4885
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B KLKB1 4177/4885TLR7 4118/4885HDAC6 11/4885
US-20120035168-A1 N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES TPMT, REN, PNMT KLKB1 4526/4885TLR7 1577/4885HDAC6 186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.